

UC San Diego

UC San Diego Previously Published Works

Title

The CBIT + TMS trial: study protocol for a two-phase randomized controlled trial testing neuromodulation to augment behavior therapy for youth with chronic tics.

Permalink

<https://escholarship.org/uc/item/531827nc>

Journal

Trials, 24(1)

ISSN

1745-6215

Authors

Conelea, Christine
Greene, Deanna J
Alexander, Jennifer
[et al.](#)

Publication Date

2023-07-01

DOI

10.1186/s13063-023-07455-1


Peer reviewed

STUDY PROTOCOL

Open Access



The CBIT + TMS trial: study protocol for a two-phase randomized controlled trial testing neuromodulation to augment behavior therapy for youth with chronic tics

Christine Conelea^{1*} , Deanna J. Greene², Jennifer Alexander¹, Kerry Houlihan¹, Sarah Hodapp¹, Brianna Wellen¹, Sunday Francis³, Bryon Mueller³, Tim Hendrickson⁴, Angela Tseng¹, Mo Chen^{3,5,6}, Mark Fiecas⁷, Kelvin Lim³, Alexander Opitz⁸ and Suma Jacob³

Abstract

Background Comprehensive Behavioral Intervention for Tics (CBIT) is a first-line treatment for tic disorders that aims to improve controllability over tics that an individual finds distressing or impairing. However, it is only effective for approximately half of patients. Supplementary motor area (SMA)-directed neurocircuitry plays a strong role in motor inhibition, and activity in this region is thought to contribute to tic expression. Targeted modulation of SMA using transcranial magnetic stimulation (TMS) may increase CBIT efficacy by improving patients' ability to implement tic controllability behaviors.

Methods The CBIT + TMS trial is a two-phase, milestone-driven early-stage randomized controlled trial. The trial will test whether augmenting CBIT with inhibitory, non-invasive stimulation of SMA with TMS modifies activity in SMA-mediated circuits and enhances tic controllability in youth ages 12–21 years with chronic tics. Phase 1 will directly compare two rTMS augmentation strategies (1 Hz rTMS vs. cTBS) vs. sham in $N=60$ participants. Quantifiable, a priori "Go/No Go Criteria" guide the decision to proceed to phase 2 and the selection of the optimal TMS regimen. Phase 2 will compare the optimal regimen vs. sham and test the link between neural target engagement and clinical outcomes in a new sample of $N=60$ participants.

Discussion This clinical trial is one of few to date testing TMS augmentation of therapy in a pediatric sample. The results will provide insight into whether TMS is a potentially viable strategy for enhancing CBIT efficacy and reveal potential neural and behavioral mechanisms of change.

Trial registration ClinicalTrials.gov [NCT04578912](https://clinicaltrials.gov/ct2/show/study/NCT04578912). Registered on October 8, 2020.

Keywords Tourette, Tic, Transcranial magnetic stimulation, Behavior therapy, Pediatric, Neuromodulation

*Correspondence:

Christine Conelea
cconelea@umn.edu

Full list of author information is available at the end of the article



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Administrative information

Note: The numbers in curly brackets in this protocol refer to the SPIRIT checklist item numbers. The order of the items has been modified to group similar items (see <http://www.equator-network.org/reporting-guidelines/spirit-2013-statement-defining-standard-protocol-items-for-clinical-trials/>).

Title {1}	The CBIT +TMS trial: study protocol for a two-phase randomized controlled trial testing neuromodulation to augment behavior therapy for youth with tics
Trial registration {2a and 2b}	ClinicalTrials.gov Identifier: NCT04578912
Protocol version {3}	February 24, 2022 Protocol version 6
Funding {4}	This research is funded by the National Institute of Mental Health of the US National Institutes of Health (R61MH123754, PI: Conelea). Other resources: This research is supported in part by the Center for Magnetic Resonance Research (NIBIB P41 EB027061 and 1S10OD017974-01 "High Performance Connectome Upgrade for Human 3 T MR Scanner"); Center for Neurobehavioral Development at the Masonic Institute for the Developing Brain, University of Minnesota; and the MnDRIVE Non-invasive Neuromodulation Laboratories, University of Minnesota.
Author details {5a}	C. Conelea: Department of Psychiatry and Behavioral Sciences, Masonic Institute for the Developing Brain, University of Minnesota, USA D.J. Greene: Department of Cognitive Science, University of California San Diego, USA J. Alexander: Department of Psychiatry and Behavioral Sciences, Masonic Institute for the Developing Brain, University of Minnesota, USA K. Houlihan: Department of Psychiatry and Behavioral Sciences, Masonic Institute for the Developing Brain, University of Minnesota, USA S. Hodapp: Department of Psychiatry and Behavioral Sciences, Masonic Institute for the Developing Brain, University of Minnesota, USA B. Wellen: Department of Psychiatry and Behavioral Sciences, Masonic Institute for the Developing Brain, University of Minnesota, USA S. Francis: Department of Psychiatry and Behavioral Sciences, University of Minnesota, USA B. Mueller: Department of Psychiatry and Behavioral Sciences, University of Minnesota, USA T. Hendrickson: University of Minnesota Informatics Institute, Masonic Institute for the Developing Brain, USA A. Tseng: Department of Psychiatry and Behavioral Sciences, Masonic Institute for the Developing Brain, University of Minnesota, USA

Name and contact information for the trial sponsor {5b}	M. Chen: Non-invasive Neuromodulation Lab, Brain Conditions, MnDRIVE Initiative, University of Minnesota, USA; Department of Psychiatry and Behavioral Sciences, University of Minnesota, USA; Neuroscience Program, Research Department, Gillette Children's Specialty Healthcare, USA M. Fiecas: School of Public Health, Division of Biostatistics, University of Minnesota, USA K. Lim: Department of Psychiatry and Behavioral Sciences, University of Minnesota, USA A. Opitz: Department of Biomedical Engineering, University of Minnesota, USA S. Jacob: Department of Psychiatry and Behavioral Sciences, University of Minnesota, USA
Role of sponsor {5c}	Investigator-initiated clinical trial C. Conelea (principal investigator) Masonic Institute for the Developing Brain 2025 E. River Pkwy, Minneapolis, MN 55414 This is an investigator-initiated clinical trial. Therefore, the funders played no role in the design of the study; collection, analysis, and interpretation of the data; and writing of the manuscript.

Introduction

Background and rationale {6a}

Chronic tics are the primary symptom of Tourette syndrome and persistent motor/vocal tic disorder [1]. Chronic tics affect 1–3% of youth [2] and are associated with adverse impacts on functioning, physical pain, diminished quality of life, peer victimization, and a fourfold increased risk of suicide compared to the general population [3–5].

Comprehensive Behavioral Intervention for Tics (CBIT [6]) is the current gold standard, first-line treatment for tics [7]. Large randomized controlled trials established the superiority of CBIT over supportive therapy in children [8] and adults [9], and meta-analyses show comparable effect sizes for CBIT and antipsychotic medications [10]. However, only 52% of children [8] and 38% of adults [9] showed clinically meaningful tic improvement in the original CBIT trials, demonstrating a need for targeted augmentation of CBIT to improve response.

The overarching goal of CBIT is to improve tic controllability—a patient's ability to voluntarily inhibit tics they find impairing or distressing. During the core CBIT procedure, known as competing response training, patients learn to engage in a competing motor action upon noticing tics or tic antecedents. Tic controllability has been shown to drive CBIT improvement [11] and predict lower tic burden

over the course of illness [12]. However, many youth lack the foundational tic inhibition ability that CBIT aspires to enhance. For example, a quantitative assessment of tic controllability using the Tic Suppression Task (TST [13]) showed that only 20% of youth can temporarily fully inhibit tics, while another 20% show no tic change or even tic worsening when attempting suppression [14]. Targeted enhancement of tic controllability is therefore one plausible way to boost CBIT response.

Tics are associated with dysfunctional activity in cortico-striatal-thalamo-cortical circuits (CSTC [15, 16], including excessive activity in sensorimotor pathways. The supplementary motor area (SMA) is a key CSTC cortical node that plays a strong role in motor inhibition [17]. Evidence implicates SMA activity and hyperconnectivity in tics. For example, neuroimaging studies show increased functional connectivity between SMA and successive nodes of the CSTC sensorimotor circuit [15], including the primary motor cortex (M1 [18, 19]). SMA activity is elevated prior to tic execution [15, 18, 20] and during periods of higher tic frequency [18, 21]. Furthermore, SMA activity and connectivity have been shown to be significantly correlated with tic severity and complexity [22] and tic premonitory urge severity [23]. Finally, SMA shows strong resting state functional connectivity (RSFC) with striatal deep brain stimulation (DBS) sites that are most effective for treating tics [24].

SMA's extensive connectivity with regions implicated in motor control and its role in tic pathology have made it a leading brain target candidate for repetitive transcranial magnetic stimulation (rTMS [25]). During rTMS, a pulsed magnetic field is produced by a small coil positioned over a targeted area on the scalp, inducing an electric current in the brain that modulates cortical activity. rTMS paradigms use trains of pulses to induce cortical effects that outlast the duration of stimulation [26]. rTMS has been explored as a tic treatment in small trials and case reports [27–30], some of which included children [31–33]. Early rTMS trials targeting the premotor and motor cortex showed no effect [29, 30]. In contrast, inhibitory stimulation of SMA using 1 Hz rTMS has been associated with reduced tic severity in case reports [27] and open-label trials [31, 33, 34]. However, small randomized trials targeting SMA inhibition with 1 Hz rTMS [35], deep TMS with the HBDL coil [28], and continuous theta burst stimulation (cTBS) did not find group-level clinically meaningful change. One 1 Hz rTMS study with null effects at 3 weeks of treatment found benefit after an extended dose (total of 6 weeks daily [35]). In the only study measuring neural correlates of treatment, Wu et al. [32] detected significant decreases in SMA activation and connectivity to bilateral M1 after a 2-day course of cTBS.

Taken together, the literature suggests that rTMS can engage SMA but may be insufficient as a monotherapy for tics. This notion is convergent with a large body of literature demonstrating that neurostimulation effects highly depend on the state of the targeted circuitry [36, 37], leading for calls to improve TMS outcomes with “functional targeting” that combines TMS with behavioral/cognitive engagement of the same circuit being modulated [38]. Few trials to date, however, have systematically tested the combination of TMS and psychotherapy.

Given that CBIT engages and relies on SMA-directed circuitry that is atypical in tic disorders, augmenting CBIT with TMS over SMA may potentiate neuroplasticity and increase CBIT efficacy. Accordingly, we designed the CBIT + TMS trial, an NIH/NIMH-funded two-phase, milestone-driven early-stage randomized controlled trial. Here, we describe the trial protocol.

Objectives {7}

The overall objective of the CBIT + TMS trial is to test whether augmenting CBIT with inhibitory, non-invasive stimulation of SMA modifies activity in SMA-mediated circuits and enhances tic controllability in young people with a tic disorder. The primary objective of phase 1 is to directly compare two rTMS regimens previously explored as monotherapies in people with tics as a dose-finding strategy (1 Hz rTMS and cTBS). Analyses will focus on testing changes in neural (fMRI-measured SMA task activation and RSFC) and behavioral (tic controllability) targets.

We will proceed to phase 2 if we meet the quantifiable study “Go/No Go Criteria.” A positive “Go” decision to move to phase 2 will require a demonstration of neural change (within-subject ANOVA effect size $\geq \eta^2 = 0.18$), safety ($\leq 20\%$ rate of adverse events judged to be treatment-related), and feasibility (80% of participants are able to complete 80% of treatment sessions). If these criteria are met, we will identify the “optimal” rTMS regimen for further testing in phase 2 using the following decision rules: (1) if one regimen is superior ($p < 0.05$) on one or both neural targets that regimen wins; (2) if regimens are equivalent for both targets, or if regimens differ by neural target, we prioritize the regimen with significantly better safety and feasibility outcomes (two-tailed t -test of $p < 0.05$). If there is still no difference, we will select cTBS as the “winner” since it is a faster, lower-resource demanding approach.

The primary objective of phase 2 is to replicate and validate the effects of the optimal rTMS regimen and test the link between neural target engagement and functional outcomes (i.e., whether changes in RSFC of SMA circuitry mediate improved tic controllability and decreased tic severity). We will also test the trajectory

of tic controllability change across the course of treatment and explore the durability of neural change through 1-month follow-up and of all measured outcomes through 6-month follow-up.

Trial design {8}

Both phases are randomized, sham-controlled, double-masked, parallel-group, superiority trials. Phase 1 is a three-arm trial (sham, 1 Hz rTMS, or cTBS; $n=20$ per group), and phase 2 is a two-arm trial (sham or active stimulation; $n=30$ per group). Randomization in both phases will be blocked on baseline Tic Suppression Task (TST) performance (tic controllability below or above 50%) and medication status (on vs. off). The flow chart of each study phase is shown in Fig. 1.

Methods: participants, interventions, and outcomes

Study setting {9}

The study will be conducted in an outpatient clinical-research setting at the University of Minnesota Masonic Institute for the Developing Brain in the United States

of America. This center specializes in research and clinical care related to neurodevelopmental conditions. Neuroimaging data will be collected at the University of Minnesota Center for Magnetic Resonance Research.

Eligibility criteria {10}

Participant eligibility determination

Interested participants will be initially screened for inclusion/exclusion criteria during a phone call. Medical records relevant to eligibility determination will be obtained from participants directly or, with a signed release of information permission form, from their healthcare provider(s). All eligibility criteria will be confirmed during the pre-treatment assessment and prior to the pre-treatment MRI and randomization.

Optional detailed eligibility assessment In some cases, it is possible that the phone screening outcome is unclear but could be clarified with an abbreviated version of the pre-treatment assessment visit focused on the specific eligibility question (e.g., whether tics meet the minimum




Fig. 1 The flow chart of each study phase

severity threshold). In these cases, a video call visit of up to 1 h will be scheduled to administer selected measures from the pre-treatment assessment list. For participants deemed eligible, data will be carried forward when possible to reduce participant burden.

The following are the inclusion criteria: (1) age 12–21 years at the time of study enrollment; (2) current chronic motor and/or vocal tic disorder meeting the DSM-5 criteria [1]: tics present for ≥ 1 year without a tic-free period of more than 3 consecutive months and tics not due to another medical condition or the direct physiological effects of a substance; (3) at least moderate tic severity, defined as a Yale Global Tic Severity Scale (YGTSS) total score ≥ 14 (≥ 9 for those with motor or vocal tics only), paralleling the criterion used in the CBIT efficacy trials [39]; (4) IQ greater than 70; (5) participants and parent/guardian (for minors) with enough English comprehension to provide consent and comprehend study measures and instructions; and (6) if taking psychotropic medication, medication status has been stable for 6 weeks with no anticipated changes during the 3-week intervention protocol.

The following are the exclusion criteria: (1) medical conditions contraindicated or associated with altered TMS risk profile, including a history of intracranial pathology, epilepsy or seizure disorders, traumatic brain injury, brain tumor, stroke, implanted medical devices or metallic objects in the head, current pregnancy or youth of child-bearing potential not using effective contraception, or any other serious medical condition; (2) inability to undergo MRI; (3) left-handedness; (4) active suicidality; (5) previous diagnosis of psychosis or cognitive disability; (6) substance abuse or dependence within the past year; (7) concurrent psychotherapy focused on tics; and (8) currently taking a neuroleptic/antipsychotic medication, as these medications are associated with altered seizure risk.

Individuals who will perform interventions

TMS operators will be staff trained according to recommended guidelines for TMS Technician training [40]. CBIT therapists will be individuals with experience delivering behavioral and cognitive-behavioral interventions with youth who have neurodevelopmental disorders. CBIT therapists will undergo training in the study protocol and receive ongoing supervision from a licensed clinician with CBIT expertise.

Who will take informed consent? {26a}

Consistent with IRB and HIPAA guidelines, trained research staff will obtain informed consent from parents

or adult participants (i.e., those age 18 years or older) and assent from minors prior to data collection at the first point of formal assessment (either the optional detailed eligibility assessment or the pre-treatment assessment visit). If any minors turn 18 years old during the course of their participation, they will be re-consented as an adult. Informed consent and assent will be documented electronically using a REDCap platform that is compliant with the US Food and Drug Administration's (FDA) 21 CFR Part 11 regulations.

Additional consent provisions for collection and use of participant data and biological specimens {26b}

Participants can optionally consent to allow us to (1) retain tic observation videos for future research and (2) submit de-identified data from this study to the National Institute of Mental Health Database (NDA) at the NIH.

Interventions

Explanation for the choice of comparators {6b}

cTBS and conventional 1 Hz rTMS are thought to have comparable effects on cortical excitability [41, 42] and similar safety profiles in pediatric samples [43, 44], though they have not previously been compared head-to-head in a pediatric clinical trial. TBS has particular advantages for a pediatric population including much shorter stimulation duration (i.e., 2–3 min for TBS vs. 20–30 min for rTMS) and lower stimulation intensity [44]. Sham stimulation enables a placebo comparator to the active conditions.

Intervention description {11a}

Participants will receive 10 treatment sessions, delivered daily on weekdays for 2 weeks. Treatment sessions will consist of TMS first, directly followed by CBIT sessions.

TMS protocol Stimulation will be delivered using a Magstim Super Rapid2 stimulator (Magstim Company Ltd., UK). A Magstim air-cooled 70-mm figure-eight coil will be used for motor threshold determination and active TMS conditions. Sham stimulation will use the Magstim sham air-cooled coil, which produces auditory signals identical to an active coil but contains a mu-metal shield that diverts the majority of the magnetic flux such that a minimal ($< 3\%$) magnetic field is delivered to the cortex.

The resting motor threshold (RMT) will be determined prior to the first TMS intervention session and used to calculate stimulation intensity for all TMS sessions. RMT is defined as the minimum magnetic flux needed to elicit a threshold EMG response (≥ 50 mV in peak-to-peak amplitude) in a resting target muscle (abductor pollicis brevis) in 5/10 trials using single-pulse TMS

administered to the contralateral hand area of the primary motor cortex.

TMS coil positioning for treatment will be individualized to account for individual differences in physiology, which are prominent in developmental samples. We will create individual finite element method (FEM) models for each participant using SimNIBS [45] and the participant's baseline anatomical MRIs [46–48]. Models will identify the coil location and orientation (x , y , z coordinates) that show the highest correlation between the modeled electric field magnitude and the positive z -values of fMRI activation from the finger tapping task, as in Baynel et al. [49].

TMS parameters are as follows: (1) 1 Hz protocol: single train of 2000 pulses at 110% RMT (33 min duration); (2) cTBS protocol: bursts of 3 pulses at 30 Hz repeated every 200 ms (5 Hz burst frequency), single uninterrupted 40 s train, 600 total pulses at 90% resting motor threshold (40 s duration); (3) sham protocol: to enhance masking, half of the sham participants will be exposed to the 1 Hz sequence and half will be exposed to the cTBS sequence.

CBIT protocol We will follow the published CBIT manual [6]. Participants will receive 10 sessions of CBIT, delivered daily on weekdays for 2 weeks. The manual specifies content for 8 sessions but is intended to be flexibly delivered, such that competing response-focused sessions can be increased in number. The manual has previously been delivered in intensive (daily) formats [50, 51]. CBIT consists of the following components: (1) psychoeducation about tics, (2) functional interventions (behavioral strategies to decrease the impact of tic-exacerbating factors), (3) competing response training, and (4) social support to bolster skills use. Given the premise for pairing CBIT and TMS, the CBIT protocol for the current study will emphasize daily competing response training and therapist-supported practice. Competing responses will be taught in a graded manner, beginning with the most distressing tics. Session 1 will include psychoeducation and creation of the tic hierarchy, and sessions 2–10 will focus on competing response training. Competing response practice will be assigned for between-session homework, and completion will be tracked via daily session forms.

Criteria for discontinuing or modifying allocated interventions {11b}

rTMS/cTBS stimulation intensity may be adjusted to improve tolerability. All such adjustments will be reviewed by a study physician and documented.

Anticipated circumstances under which participants will be withdrawn from the research without their

consent include (1) the participant no longer meets the inclusion/exclusion criteria; (2) study investigators decide that the participant has an emotional, physical, or behavioral reaction that poses a safety concern or interferes with data collection (e.g., poor compliance with instructions, too much anxiety to comfortably proceed with a task); (3) significantly deteriorating clinical course (e.g., emergence of acute suicidality); (4) significant adverse reaction to TMS; or (5) serious physical illness. Consistent with informed consent procedures, participants will be free to decide to withdraw at any time for any reason.

Strategies to improve adherence to interventions {11c}

During TMS delivery, coil placement and orientation will be continually monitored using a stereotaxic neuronavigation system (BrainSight 2.3.5, Rogue Research, Montreal, Quebec, Canada). To ensure CBIT protocol adherence, sessions will be video-recorded, and a randomly selected 20% will be rated by a psychologist with expertise in CBIT using established compliance forms. Patient CBIT compliance will be tracked by the therapist at each session.

Relevant concomitant care permitted or prohibited during the trial {11d}

To increase the external validity of findings, we will include participants taking psychotropic medications that have been stable for 6 weeks and expect to remain stable for the approximately 3-week treatment protocol. Those who previously received tic-specific therapy will be included if they meet the tic severity criterion. Youth receiving other forms of psychotherapy will be included provided these treatments are not focused on tics. All concurrent treatments will be monitored during the study period.

Provisions for post-trial care {30}

The study does not include specific provisions for ancillary or post-trial care. Referrals for clinical care will be provided to participants/parents who ask for this information. If licensed clinical study staff feel that a participant is likely to benefit from additional clinical care for tics or another diagnosis, participants/parents will be given relevant recommendations and referrals.

Outcomes {12}

Study assessment measures are listed in Table 1.

Phase 1

Primary outcomes focus on neural change. The primary measure will be the within-subject change in

Table 1 Study assessment measures in both phases

Assessment measure	Purpose	Reporter	Administration time				
			Screen	Pre-Tx	Sessions	Post-Tx	Follow-up
Screening [52, 53]	Eligibility and safety screening	AP or P	X				
Medical records	Current medications, relevant/available documents; for eligibility determination	AP or P	X				
Demographics	Sample characteristics	AP or P		X			
Wechsler Abbreviated Scale of Intelligence [54]	Eligibility	AP or CP		X			
MINI 7 KID [55] or adult [56]	Structured diagnostic interview	IE		X			
Yale Global Tic Severity Scale, YGTSS [57]	Measure of tic severity and checklist of specific tic types	IE		X		X	X
Tic Suppression Task (TST) [14, 58]	Direct observation measure of tic controllability	AP or CP		X	X	X	X
Parent/Adult Tic Questionnaire [59, 60]	Measure of tic symptoms and severity	AP or P		X		X	X
Premonitory Urge for Tics Scale [61, 62]	Measure of intensity of urges to tic	AP or CP		X		X	X
Child/Adult Behavior Checklist [63, 64]	Measure of broad emotional and behavioral functioning	AP or P		X		X	X
Sheehan Disability Scale [65]	Measure of functional impairment	AP or CP and P		X		X	X
Tic Impact Questions	Measures of how tics impact daily function	AP or CP and P		X		X	X
Behavior Rating Inventory of Executive Function [66]	Measure of impairment of executive function	AP or CP and P		X		X	X
Ask Suicide-Screening Questions (ASQ)	Suicidality screen	IE		X		X	X
TMS Adverse Effects Questionnaire [53]	Tracks side effects of TMS	Staff IE			X	X	X
Clinical Global Impressions (CGI)	Global measure of illness severity and improvement	IE AP or CP P		X		X	X
Stimulation context tracking form	Participant behavior and emotional state during rTMS stimulation	Staff			X		
Masking form	Assess belief about whether participant got active or placebo TMS	AP or CP, P, IE, staff				X	
Concurrent Treatment Tracking Form	Record of all medications and dosages, psychotherapy	Staff		X	X	X	X
Client Satisfaction Questionnaire [67]	Assess patient satisfaction with the intervention	AP or P				X	X

AP adult participant, CP child participant, IE independent evaluator, P parent, Tx treatment

SMA activation from pre- to post-treatment, as assessed by participant blood oxygenation level-dependent (BOLD) signal during the fMRI motor task (bilateral finger tapping). The secondary measure of neural target engagement will be the within-subject change in RSFC of SMA-mediated brain circuits from pre- to post-treatment (SMA-DLS, SMA-M1).

We will also examine several other outcomes. First, we will evaluate within-subject change in tic controllability from pre- to post-treatment as measured by the TST. Second, we will assess safety and feasibility, as measured at baseline, post-treatment, daily treatment sessions, and 1- and 3-month follow-ups using staff-administered forms, aggregated as the number of treatment-related

adverse events and tolerability ratings of side effects. Finally, we will explore the between-group differences in measures of clinical functioning from pre- to post-treatment and over the 1- and 3-month follow-up period (Yale Global Tic Severity Scale, Premonitory Urge for Tics Scale, Child/Adult Behavior Checklist, Sheehan Disability Scale, Behavior Rating Inventory of Executive Functioning) and treatment satisfaction (Client Satisfaction Questionnaire).

Phase 2

The primary outcome is the within-subject change in RSFC task activation of SMA-mediated brain circuits from pre- to post-treatment and its relationship to (1)

treatment group assignment, (2) within-subject change in TST-measured tic controllability, and (3) within-subject change in the Total Score of the YGTSS. Secondary analyses will (1) describe the trajectory of change in tic controllability across daily treatment sessions and (2) explore the durability of change in RSFC of SMA-mediated circuits through the 1-month follow-up and clinical outcomes through 6-month follow-up.

Participant timeline {13}

Participant-facing activities are depicted in Fig. 1. Participants who meet the initial eligibility screening criteria (on-phone screening and, in some cases, also the optional detailed eligibility assessment) will be scheduled for the “pre-treatment assessment,” at which time consent/assent and pre-treatment measures and MRIs will be completed. Daily sessions of CBIT + TMS will begin within 10 calendar days of the pre-treatment assessment, with a targeted window of 2–3 business days (to allow for runtime and checking of the targeting pipeline). Participants will complete 10 CBIT + TMS visits within 13 business days. The post-treatment visit will be completed within the 10 calendar days following the last CBIT + TMS visit, with a targeted window of 1–3 business days. Post-treatment follow-up MRI scans will occur at least 24 h after the last TMS session to ensure that observed neural activity is not simply the acute aftereffect of TMS. The 1-month assessment will be completed 4–6 weeks after the last CBIT + TMS visit, and the 3-month assessment will be completed 12–14 weeks after the last CBIT + TMS visit. In phase 2, the additional 6-month assessment will be completed 24–26 weeks after the last CBIT + TMS visit.

Sample size {14}

Power analyses were calculated for our sample sizes (phase 1 = 60, phase 2 = 60) assuming 20% attrition (phase 1 = 48, phase 2 = 48). A sample of $N = 48$ gives us 80% power to detect an effect size of at least $\eta^2 = 0.18$ for differences in SMA activation between active TMS and sham and least $\eta^2 = 0.18$ for differences in RSFC between active TMS and sham. This sample will give us 80% power to detect an effect size of at least $d = 0.90$ for a within-subject improvement in tic controllability in phase 1 and an effect size of at least $d = 0.58$ to test change in tic control trajectory across the groups in phase 2. For phase 2's exploration of the durability of change, using simulations, assuming a moderate correlation of 0.5 on the RSFC or the clinical outcomes within a participant across the times of assessment, we have at least 80% power to detect a standardized difference of at least $d = 0.71$ between the treatment and sham groups on functional connectivity or the functional outcomes.

Recruitment {15}

Recruitment strategies will include the dissemination of study information to clinicians within the university-affiliated MHealth Fairview hospital system and in community practices across the region, focusing on those clinicians most likely to encounter individuals with tics (i.e., neurologists, psychiatrists, primary care practitioners). We will use an IRB-approved process to send messages to potentially eligible patients via the MHealth Fairview electronic medical record system. Flyers describing the study will be distributed in public physical spaces (e.g., libraries, community events) and posted on departmental websites and lab social media accounts.

Assignment of interventions: allocation

Sequence generation {16a}

Block randomization, stratified on baseline TST performance (tic controllability below or above 50%) and medication status (on vs. off), with equal block sizes will be carried out using the `blockrand` package in R [52]. For phase 1, the blocks are of size 6, designed in a manner so that the odds of allocation to 1 Hz rTMS vs. cTBS is 1:1, and the odds of allocation to active vs. sham is 2:1. For phase 2, the blocks are of size 2, designed so odds of allocation to active vs. sham are 1:1. The randomization key is a digital file stored in a place only accessible to unmasked staff (TMS supervisor and statistician).

Concealment mechanism {16b}

Conditions are concealed within the digital randomization file.

Implementation {16c}

The study staff will send stratification information obtained from the pre-assessment visit to the study statistician via a REDCap form. After the statistician has completed the randomization, the TMS supervisor verifies the randomization. TMS operators are informed of protocol type (1 Hz or cTBS) and coil (where active vs. sham coils are concealed with coded letters, i.e., A or B). A separate active coil is used for RMT determination to enhance coil masking.

Assignment of interventions: blinding

Who will be blinded {17a}

Procedures will be implemented to control for expectancy effects related to TMS stimulation. Persons who will be masked to TMS status (active vs. sham) are participants, parents (if applicable), and study staff administering the clinical assessments, coding the TST videos, delivering the CBIT therapy, and collecting the MRI data.

Unmasked personnel will be the study statistician and the TMS operator supervisor. The TMS operator, participant, and parents will be masked to active vs. sham status in phase 1 but will be aware of 1 Hz vs. cTBS allocation; they will be fully masked in phase 2. The staff who administer the clinical rating scales and code the TST videos will not be present for a given participant's CBIT + TMS visits to ensure masking to overall therapy progress. At post-treatment, forms assessing masking adequacy will be given to participants, parents, and masked staff who conduct CBIT sessions and assessment visits.

Procedure for unblinding if needed {17b}

Unmasking of TMS status will occur in situations where the staff deem this necessary for participant safety, to address a technical issue related to the TMS device, or another unforeseen situation in which TMS status is critical for study conduct. Unmasking will be limited to those individuals deemed most critical for addressing the inciting situation. Independent evaluators (i.e., staff responsible for conducting pre-, post-, and follow-up assessments with participants) will not be intentionally unmasked to ensure that clinical functioning can be tracked by a staff member who is otherwise unfamiliar with the course of treatment.

Data collection and management

Plans for assessment and collection of outcomes {18a}

Clinical assessment measures and timing are listed in Table 1. The clinician conducting the pre-treatment, post-treatment, and follow-up assessments will be an independent evaluator (IE) masked to all treatment-related information. IEs will be research staff at least at the BA/BS level trained to criterion on all study measures who meet weekly with a licensed clinician supervisor for criterion maintenance. Assessments will be video-recorded, and a random 20% will be reviewed to prevent drift.

Treatment measures Treatment measures will include separate daily CBIT and TMS session notes, the TMS Adverse Events Questionnaire, and the Concomitant Medications and Therapy Tracking Form, which will be completed by the relevant staff member (TMS operator or CBIT therapist). All clinical assessment and treatment measures will be entered into REDCap and double-checked for completion and accuracy by a second staff member within 2 business days of the study visit.

Tic Suppression Task (TST) In this paradigm, a participant is seated alone in a room (to reduce observation reactivity effects [53]) in front of a GoPro video camera

and computer that provides condition instructions. The TST will consist of 2 3-min conditions: (1) rest—youth is instructed to stay seated and tic freely, a measure of naturally occurring tic frequency; (2) suppression—youth is instructed to suppress tics. Participants are prompted every 30 s to verbally state a premonitory urge using a visual 0–10 scale.

Coding Following established tic coding steps [54], videos will be coded using DataVyu [55] to establish tic frequencies (tics per minute for each condition). Coders will be masked to time (i.e., whether the clip is pre- or post-treatment), TMS status, and TST condition. An independent rater will code 20% of videos to establish interrater reliability. Reliability will be calculated as percent agreement for each video clip, where agreement will be defined as a code of tic occurrence within a 1-s tolerability window. The primary rater's coding will be considered valid with $\geq 80\%$ agreement; clips with the lower agreement will warrant additional training and re-coding. Final interrater reliability for all videos will be calculated using intraclass correlation coefficients and Cohen's kappa [56]. The primary TST outcome will be tic controllability, calculated as a percent change score [(“Free to Tic” tic frequency – Suppression tic frequency) / “Free to Tic” tic frequency $\times 100$] [14]. Positive values indicate tic reduction during suppression (i.e., better suppression), near-zero values indicate little to no difference between conditions (i.e., poor suppression), and negative values indicate tic increase during suppression (i.e., tic worsening during suppression condition). We will calculate this value for each administration of the TST.

MRI and fMRI data acquisition A Siemens Prisma 3-T scanner will be used for image acquisition. To minimize head motion during the scan, we will immobilize the participant's head with foam wedges that fit snugly between the head and the 32-channel receive-only head coil. We will implement real-time monitoring of subject motion during all fMRI scans using framewise integrated real-time MRI monitoring (FIRMM) [57, 58] allowing us to scan to criterion (at least 5 min of usable data). As needed, we will re-run scans or bring back participants for a repeat scan session. We will acquire scans based on the ABCD acquisition protocol and pulse sequences:

- 1) Structural scans for anatomical reference, including (a) whole brain 3D sagittal T1 weighted inversion prepared RF-spoiled gradient echo scan which includes motion-driven selective reacquisi-

tion of k -space to compensate for subject motion (TR=2500 ms, TE=2.9 ms, TI=1070 ms, 1.0 mm isotropic voxel, flip angle=8° (7 min)) and (b) whole brain 3D sagittal T2-weighted variable flip angle fast spin echo scan which includes motion-driven selective reacquisition of k -space to compensate for subject motion (TR=3200 ms, TE=565 ms, 1.0 mm isotropic voxel, variable flip angle (6 min)).

2) Resting fMRI: whole brain acquisition using the ABCD SMS sequence (60 axial slices, 2.4 mm isotropic voxel size, TR=800 ms, TE=30 ms, FOV=216 mm, matrix=90×90, MB factor=6, 383 volumes (5 min)). During this scan, participants will be instructed to keep their eyes open and orient to a fixation cross. Four runs of the resting scan will be collected during each visit.

3) Spin echo fMRI reverse phase encode scan pair: whole brain acquisition using the ABCD SMS spin echo sequence (60 axial slices, 2.4 mm isotropic voxel size, TR=7030 ms, TE=80 ms, FOV=216 mm, matrix=90×90, 1 volume pair (0.5 min)).

4) Finger tapping task, for functional localization of SMA. Whole brain acquisition using ABCD SMS sequence (60 axial slices, 2.4 mm isotropic voxel size, TR=800 ms, TE=30 ms, FOV=216 mm, matrix=90×90, MB factor=6, 394 volume (5.5 min)). The task involves alternating 15-s blocks of simultaneous bilateral finger tapping and rest, cued by visual stimuli. This task is used to isolate neural activity in motor planning and execution areas, including SMA, and is a highly reliable, well-established fMRI task used for motor mapping [59] and for TMS targeting of the motor cortex and SMA by our group and others [32].

MRI and fMRI pre-processing The ABCD-BIDS pre-processing pipelines will be applied to the structural T1 and T2 data as well as the resting state data [60]. We will use established, rigorous approaches for mitigating head motion artifacts [61–63] that have been shown to be effective for studies of group or individual differences [64, 65].

Tasks for TMS coil placement Processing and analysis for finger tapping task data will also be carried out using the ABCD-BIDS processing pipeline. We will conduct a whole-brain linear regression analysis with the contrast of interest rest vs. active tapping, yielding a whole-brain activation map for each person. Activation within the SMA will be mapped onto the subject's T1, the weighted centroid for the activation will be computed, and this coordinate will be used for coil placement in the individual electric field models.

Plans to promote participant retention and complete follow-up {18b}

Efforts will be made to reduce barriers to attending study visits, including offering study visits at preferred times, sibling care during study visits, and remote options for the completion of study tasks that do not need to be conducted in person (e.g., clinical assessments). We will use an Adjunctive Services and Attrition Plan (ASAP) to address any situations that require intervention by the study staff beyond that afforded by the assigned treatment condition. Participants will be allowed up to 1 ASAP session during the acute treatment phase and 1 during the follow-up period. Participants will be compensated for all study activities, with increasing amounts of compensation in the follow-up period to promote retention.

For participants who discontinue or deviate from intervention protocols, we will aim to complete at least one final clinical assessment. We will attempt to provide participants with appropriate care referrals in the event of any withdrawals or drop-outs.

Data management {19}

This study will utilize the secure, web-based Research Electronic Data Capture (REDCap) system for data input. Range checks for data values and missing data will be automatically flagged in REDCap. All REDCap data will be double-checked by a second staff member to ensure data integrity. Imaging data will be de-identified and stored on secure servers. TST and visit videos will be stored on Box, a HIPAA-compliant file storage platform, and analyzed on secure computers/servers. Access to password-protected databases will be limited to the investigators and trained staff listed on the study IRB, in accordance with institutional policy. Data file archiving and back-up will be performed on a regular basis.

Confidentiality {27}

All members of the project will maintain up-to-date certification on research participant confidentiality and privacy through the Collaborative Institutional Training Initiative (CITI) curriculum. The study staff will additionally participate in HIPAA and PHI training through UMN. All data will be identified and labeled only by subject ID numbers, which will be stored separately from the identifying information and from consent and assent forms.

Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in this trial/future use {33}

Not applicable, as no biological specimens are collected.

Statistical methods

Statistical methods for primary and secondary outcomes {20a}

Phase 1

Primary outcome (SMA activation) An ROI analysis will be performed to determine the time \times treatment group differences in SMA activation elicited by the fMRI motor task (finger tapping). The SMA ROI will be identified by placing a seed (sphere with 5 mm radius) that matches the coordinate used for individual TMS coil placement. Activation parameters in the SMA will be identified in a first-level analysis, using a general linear model (GLM) to model each subject's BOLD time course during the motor task. These activation parameters will be used in a subsequent linear mixed effects (LME) model. The predictors of the LME will include the baseline activation, group indicators for the stimulation groups, and baseline \times group interactions. Random effects will be used to model within-subject variation from the first-level analyses. Altogether, the LME will allow us to model how the within-subject change in activation from pre-treatment to post-treatment differs across active and sham conditions.

Secondary outcome (SMA connectivity) We will use a seed-based analysis approach to test RSFC between a priori ROIs and use a false discovery rate (FDR) correction for multiple comparisons threshold of $p < 0.05$. Functional connectivity analyses will be conducted by placing a seed (sphere with 5 mm radius) in each ROI. SMA seeds will match the coordinates used for individual TMS coil placement. We will similarly individually identify ROI seeds for the left and right primary motor cortex using finger tapping task data. Right and left DLS (i.e., putamen) ROIs will be individually anatomically based and identified using FreeSurfer anatomical masks on each participant's T1 volume aligned to each participant's rs-fMRI data using `bbregister` [66], mirroring our prior work [67]. Average BOLD time-series data will be extracted from each ROI, for each participant, and used to calculate correlation coefficients with SMA. These will be converted to individual z -scores using Fisher's transformation, yielding the indices representing RSFC between the seed and each of the targets (4 connections). ANOVA will be used to model how the within-subject change in functional connectivity from pre-treatment to post-treatment differs across active and sham conditions. Effect sizes from the ANOVA will be computed to determine target engagement.

In addition, we will also investigate the effects of each TMS regimen on the connectivity in other nodes of

CSTC circuits. To this end, we will extract the ROI-level time courses from each region in the CSTC, and we will use partial correlations to obtain an estimate of connectivity between each ROI pair within the CSTC while accounting for the data observed in the other ROIs. Given the collection of partial correlations for each study participant, we will use the sum-of-powers (SPU) test, which uses the collection of partial correlations simultaneously, to assess for group differences across the sham and TMS regimens [68]. While changes in SMA-M1 or SMA-DLS will suffice to satisfy milestone 1 in our *Go Criteria*, testing additional functional connections will broaden our investigations into the CSTC when assessing the target engagement of each regimen.

Other outcomes TST "tic controllability" scores [14] will serve as the primary outcome in an ANOVA model, which will be used to establish if there exist differences in how the 1 Hz, cTBS, and sham conditions affect change in tic suppression ability from pre- to post-treatment. Group indicators for these conditions will be the primary predictors for the model.

Phase 2

Primary outcome (SMA connectivity and its relationship to clinical outcomes) The analysis will be conducted using ANCOVA. Primary predictors are group indicators for sham and active TMS. Dependent variables are the differences in global tic severity (YGTSS) pre- and post-treatment. Differences pre- and post-treatment in RSFC and its interaction with the group indicators will be included as potential mediators for the dependent variable.

As in phase 1, we will use a seed-based analysis approach to measure RSFC between a priori ROIs (SMA-DLS and SMA-M1). However, it is possible that change will occur outside of these a priori selected networks. Thus, we will also conduct a more comprehensive network analysis. For each subject, we will measure functional connectivity by calculating interregional partial correlations across a set of 300 ROIs that comprehensively samples cortex, subcortex, and cerebellum [69]. This set of 300 ROIs can be broken down into a number of functional brain networks (e.g., fronto-parietal, cingulo-opercular, default-mode, somatomotor). Given the large number of ROIs relative to the proposed sample size, to estimate the partial correlations, we will use the graphical lasso [70], which is a reliable approach for estimating partial correlations [71]. Finally, we will average the correlations

within nodes of a network and between nodes of different networks to yield composite scores reflecting intra-network and inter-network integrity [72]. ANOVA will be used to model how the within-subject change in functional connectivity from pre-treatment to post-treatment differs across active and sham conditions. Effect sizes from the ANOVA will be computed to determine target engagement.

Secondary outcome (trajectory of change in tic controllability) We will identify the potentially non-linear relationship between the number of treatment days for each subject and their change in tic controllability on the TST. We will fit different dose–response models using non-linear least squares, and then identify the best fitting model using Akaike (AIC) or Bayesian information criteria (BIC [73]). Using the fitted dose–response curve, we will find the lowest number of days that leads to 90% of the maximum effect [74].

Secondary outcome (intervention durability) The durability of changes in SMA-M1 and SMA-DLS functional connectivity and clinical outcomes will be measured through 1 month follow-up. Linear mixed models (LMMs) will be used to model the trajectories of each of the functional connectivity measures and clinical outcomes across the times of assessment. Durability will be assessed by quantifying the role of time in each of the functional connectivity and clinical outcomes.

Interim analyses {21b}

No interim analyses are pre-specified for this trial. As part of performing risk/benefit assessments, the study Data Safety Monitoring Board (DSMB) can request interim efficacy information in addition to available safety data. The study does not have any formal stopping rules. The DSMB votes on study continuation at each meeting.

Methods for additional analyses (e.g., subgroup analyses) {20b}

None planned.

Methods in analysis to handle protocol non-adherence and any statistical methods to handle missing data {20c}

We will carry out the analyses of the data according to the intention-to-treat principle. We will compare the baseline characteristics of those who drop out vs. those who do not and adjust models based on significant predictors of dropout. For those who drop out during the follow-up period or miss some assessments during follow-up, we will use multiple imputation by chained

equations (MICE) to allow for missing data without loss of those cases from the model under the assumption of missing at random (MAR). If dropout status appears to be missing not at random (MNAR), i.e., dropout is associated with an unobserved outcome, we will run sensitivity analyses using MICE to compare imputed and non-imputed model results to assess the robustness of statistical inference.

Plans to give access to the full protocol, participant-level data, and statistical code {31c}

Participant-level de-identified data will be submitted to the National Institute of Mental Health Data Archive (NDA, Collection #3650). Participants can opt into joining a videographic data registry that is held by the PI; this identifiable videographic can be shared with qualified researchers at NIH-recognized research institutions via a rigorous approval system, in accordance with our IRB and institutional guidelines. R code for statistical analyses can be made available upon reasonable request. The MRI pdf and/or exar1 scanning protocol can be made available upon request.

Oversight and monitoring

Composition of the coordinating center and trial steering committee {5d}

Study governance for this single-site study is organized into “teams” with specific responsibilities, including the oversight team, recruitment team, intervention deployment team, data management team, neuromodulation team, and neuroimaging team. The oversight team is led by the PI and is responsible for global oversight of study conduct, procedural and scientific integrity, regulatory management, data quality assurance, data analysis, and dissemination of findings. Each team is led by a doctoral-level co-investigator. Each team works with the oversight team to develop and monitor standard operating procedures. Each team has a weekly meeting with the PI focused on decisions and progress within their scope of responsibility. Full study meetings are held quarterly and as-needed.

Composition of the data monitoring committee, its role, and reporting structure {21a}

An independent DSMB has been convened for this study. Members must be independent of any conflict of interest with the research project and study investigators, in accordance with NIMH policy [75]. Members include a biostatistician with expertise in randomized clinical trial methodology, a researcher with expertise in neurodevelopmental disorders, and a child/adolescent psychiatrist. A study-specific DSMB charter was created prior to the enrollment of the first participant. The DSMB is advisory

to the PI. The PI holds ultimate responsibility for decisions regarding the trial.

The DSMB will meet annually to (1) monitor study safety, quality, and conduct and (2) decide whether adequate participant safeguards are in place. The DSMB will review the (1) study progress, including assessments of data quality and participant recruitment, accrual, and retention; (2) outcome and adverse event data, to determine whether there is any change to the anticipated benefit-to-risk ratio; (3) relevant external information that may have an impact on study ethics or participant safety; and (4) study procedures for privacy and confidentiality. The DSMB will review de-identified reports annually. At each meeting, the DSMB will vote to continue the trial unchanged, continue the trial with modifications, or terminate the trial. The DSMB may also make recommendations about other aspects of the trial such as the recruitment of participants and the conduct of the trial.

At any time during the trial, regulatory authorities and any other body or individual involved with the conduct of the trial may seek the advice of the DSMB about any concern that they may have about the conduct, outcome, or continuation of the trial. Any such requests are directed to the DSMB Chairperson.

Adverse event reporting and harms {22}

The study staff will formally assess for adverse events at each post-randomization study visit using the comprehensive study adverse events questionnaire. All adverse events are reviewed by the PI. Per the DSMB charter, key events include (1) seizures, (2) side effects to the study treatment, (3) hospitalization, (4) suicidality, and (5) premature drop-out from treatment. Data will indicate *likely, possible, or unlikely* relation to study interventions.

Any unexpected serious adverse events or unanticipated problems involving risks to participants that are possibly related to rTMS will be promptly reported to the Chair of the DSMB, IRB, FDA, and assigned NIMH Project Officer in accordance with relevant rules and regulations. Investigators will submit yearly progress reports to IRB and FDA summarizing data and safety monitoring activities, including adverse events deemed expected or unrelated to the study and protocol deviations that do not affect the scientific soundness of the research plans or the rights, safety, or welfare of participants.

Frequency and plans for auditing trial conduct {23}

The NIMH CTOB Clinical Research Education, Support, and Training Program (CREST) will provide ongoing regulatory monitoring. Planned monitoring visits will occur upon study initiation, yearly, and after completion of data collection. The monitoring schedule may be revised based on considerations such as accrual rate, protocol

deviations, magnitude of data corrections required, or DSMB recommendation.

Plans for communicating important protocol amendments to relevant parties (e.g., trial participants, ethical committees) {25}

Protocol changes will not be implemented without prior IRB approval. Investigators will follow FDA regulations that govern significant risk device investigations [76]. These require FDA review and approval prior to making significant changes in the study protocol or in informed consent that may increase participant risk or impact the scientific soundness of the study. Protocol changes will be indicated on ClinicalTrials.gov. If any amendments result in changes to informed consent, participants who have not completed the study will be re-consented/assented.

Dissemination plans {31a}

The results will be submitted to ClinicalTrials.gov via the Protocol Registration and Results System Information Website. Informed consent will have a specific statement informing participants that results from the study will be posted on ClinicalTrials.gov.

Discussion

The present CBIT + TMS trial is designed to test whether augmenting CBIT with inhibitory, non-invasive stimulation of SMA via TMS procedures modifies activity in SMA-mediated circuits and enhances tic controllability in young people with tic disorders.

This trial is the first test of combined brain stimulation and CBIT focused on comparing brain stimulation strategies. The results will provide insight into whether brain stimulation can augment CBIT, a goal that is important, given that 50% of patients do not benefit from CBIT alone. Collection and analysis of multimodal data (neural, behavioral, clinical) will inform our understanding of the mechanisms underlying tic etiology, maintenance, and treatment response. The study applies a functional targeting approach, wherein the two intervention modalities are matched based on the premise that TMS and CBIT-elicited behaviors are synergistically engaging common neurocircuitry (i.e., CBIT and the TMS protocols are both engaging sensorimotor circuitry to support tic control behavior). As we have articulated elsewhere [77], TMS approaches to augment cognitive-behavioral therapies are most likely to be positively synergistic when the interventions activate common, complementary, or compensatory circuits that support CBT-elicited behaviors.

Notably, this study will be one of few clinical trials to date examining TMS as an intervention for a pediatric sample. TMS is a potentially promising modality for targeting aberrant brain circuitry involved in developmental

neurological and psychiatric illnesses. TMS in children has been demonstrated to be safe, comfortable, and well-tolerated, and it has minimal side effects [78]. This study will add to our understanding of pediatric TMS efficacy, tolerability, and safety.

Limitations and anticipated challenges

Tic-related excessive and uncontrollable movements can present challenges to fMRI data collection and TMS administration. We are implementing several processes to mitigate this challenge. First, for MRI data acquisition, we will employ a tool (FIRMM) for assessing real-time movement. This will enable us to determine if data meet our motion quality criteria in real time, so we can adjust, extend, or repeat scanning visits [57, 58]. Additionally, we will use established strategies for obtaining high-quality fMRI data from youth with tics [58] and data-processing procedures to adjust for motion [62, 63]. For TMS administration, we have worked with Child Life specialists in our institute and used patient and parent feedback to implement measures that increase comfort and tolerability (e.g., use of supportive pillows and/or a weighted blanket to stabilize the body, allowing participants to bring comfort objects). TMS coil placement will be continually tracked with the Brainsight software, and the staff will document the percentage of “on target” pulses and participant-rated efforts to actively suppress tics during stimulation. Our study will enable us to explore the effectiveness of these strategies and methodologies for use in future study designs.

Although previous CBIT efficacy trials [8, 9] implemented CBIT in 8 sessions over 10 weeks, we will conduct treatment sessions daily versus weekly to maintain consistency with TMS protocols and key principles [79–81]. Although this results in CBIT administration that deviates from typical outpatient setting protocols, CBIT was designed to be delivered flexibly, and studies that have examined flexible delivery have found it to be feasible and effective [50, 51]. Comparing our observed effect size for tic severity (YGTSS) change to those reported in other CBIT efficacy studies will help us understand the extent to which this format is comparable. Phase 2 analyses examining the trajectory of change in tic controllability across treatment will also inform our understanding of dose–response relationships. Finally, session-level data collection will be examined retrospectively to explore whether certain CBIT process elements may relate to outcomes in this format (e.g., number of tics targeted in treatment, homework compliance).

A final limitation worth noting is the intensive scheduling requirements, such that the participant burden for the study is elevated for the intervention portions of each phase. Unanticipated schedule changes may

affect protocol timing. To mitigate these challenges, we will provide a high level of support from research staff surrounding scheduling logistics, plan for maximum scheduling flexibility (e.g., after business hours and offering TMS visits on weekends as necessary) and provide schedules that are planned around breaks (e.g., school break in the summer). We will document feedback from those who choose to participate as well as those who decline participation to understand the extent to which the intervention schedule may impact accessibility.

Trial status

This report is based on protocol version 6 (February 24, 2022). Recruitment began in December 2020. The recruitment pace was slower than anticipated due to circumstances and restrictions related to the COVID-19 pandemic. Recruitment for phase 1 is expected to be complete by January 2024. If phase 1 milestones are met, phase 2 is anticipated to begin shortly after phase 1 completion and to have a duration of 3 years.

Abbreviations

CBIT	Comprehensive Behavioral Intervention for Tics
CSTC	Cortico-striatal-thalamo-cortical circuit
SMA	Supplementary motor area
M1	Primary motor cortex
RSFC	Resting state functional connectivity
DBS	Deep brain stimulation
rTMS/TMS	Repetitive/transcranial magnetic stimulation
cTBS/TBS	Continuous/theta burst stimulation
fMRI/MRI	Functional/magnetic resonance imaging
DSMB	Data Safety Monitoring Board
IRB	Institutional Review Board
FDA	United States Food and Drug Administration
NDA	National Institute of Mental Health Database
PI	Principal investigator
RMT	Resting motor threshold
FEM	Finite element method
TST	Tic Suppression Task
FIRMM	Frame-wise integrated real-time MRI monitoring
IE	Independent evaluator
ASAP	Adjunctive Services and Attrition Prevention
REDCap	Research Electronic Data Capture
CITI	Collaborative Institutional Training Initiative
ROI	Region of interest
GLM	General linear model
LME	Linear mixed effects
FDR	False discovery rate
MAR	Missing at random
MNAR	Missing not at random
LMM	Linear mixed models
MICE	Multiple imputation by chained equations
NIMH	National Institute of Mental Health
CREST	Clinical Research Education, Support, and Training Program
CNBD	Center for Neurobehavioral Development
NNL	Non-invasive Neuromodulation Laboratory
CMRR	Center for Magnetic Resonance Research

Acknowledgements

We thank Cala Hefferan, MA, Certified Child Life Specialist, for supporting the development of procedures to increase participant comfort.

Authors' contributions {31b}

CC is the principal investigator and conceived the study, led the proposal and protocol development, and is responsible for the overall study design and conduct. DJG contributed to the study design and to the development of the proposal and neuroimaging protocol. JA led the CBIT protocol development. KH and SH contributed to the development of the study protocols. BW contributed to the protocol and data management procedures. SF contributed to the development of the proposal and protocol development. BM is the study MR physicist and contributed to the proposal and protocol development. TH is the lead neuroimaging data analyst and contributed to the protocol development. MC is the TMS study supervisor and contributed to the protocol development. AT contributed to the protocol development and implementation of neuroimaging procedures. MF is the study biostatistician. KL contributed to the proposal and protocol development. AO contributed to the proposal and protocol development related to TMS targeting. SJ is the study psychiatrist and contributed to the proposal, protocol development, and design of the study safety monitoring procedures. All authors read and approved the final manuscript.

Funding {4}

Research reported in this publication was supported by the National Institute of Mental Health (NIMH) of the National Institutes of Health under award number R61MH123754. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Additional resources in the form of space and equipment access are provided by the Center for Magnetic Resonance Research (NIBIB P41 EB027061 and 1S10OD017974-01 "High Performance Connectome Upgrade for Human 3 T MR Scanner"); Center for Neurobehavioral Development at the Masonic Institute for the Developing Brain, University of Minnesota; and the MnDRIVE Non-invasive Neuromodulation Laboratories, University of Minnesota.

Availability of data and materials {29}

Data will be submitted to the NDA every 6 months and held privately until shared with the research community. In accordance with NIMH expectations at the time of the funding award, "data will be shared with the research community when papers using the data have been accepted for publication or at the end of the award period, whichever is sooner" [82]. Specific data used for each resulting publication will be shared as NDA studies when papers are accepted for publication.

Declarations**Ethics approval and consent to participate {24}**

This study was approved by the University of Minnesota Institutional Review Board (FWA00000312). Written informed consent from parents or adult participants (i.e., those age 18 years or older) and assent from minors will be obtained from all participants. If any minors turn 18 years old during the course of their participation, they will be re-consented to provide written informed consent as an adult.

An investigational device exemption for the use of the Magstim Super Rapid2 Stimulator rTMS Machine in this study was obtained from the United States Food and Drug Administration (FDA, Approval #G200176).

Consent for publication {32}

Not applicable.

Competing interests {28}

CC has received speaking honoraria and travel reimbursement from the Tourette Association of America (TAA), salary support from the University of Minnesota MnDRIVE initiative, and research funding from the US National Institutes of Health (NIH), National Science Foundation (NSF), Minnesota Robotics Institute, Masonic Charities, and Posit Science via NIH-funded grants (R43MH121209, R43MH124542).

AO is an inventor on patents and patent applications describing methods and devices for non-invasive brain stimulation. AO has equity in the startup StimPhase which develops brain stimulation technologies. AO has received research funding from the NIH, NSF, the University of Minnesota MnDRIVE Initiative, and the Minnesota Partnership for Biotechnology & Medical Genomics. MF has received research funding from the NIH.

DJG has served as a consultant for Turing Medical, the developers of FIRMM software, and has received research funding from the NIH.

KL has received research funding from the NIH and the Department of Veterans Affairs.

SJ has received grant support from the NIH, Department of Defense (DOD), SFARI Foundation, and Roche and has attended advisory boards for Fraser, Roche, and Minnesota Independence College & Community.

JA, KH, SH, BW, SF, BM, AT, TH, and MC declare that they have no competing interests.

Author details

¹Department of Psychiatry and Behavioral Sciences, Masonic Institute for the Developing Brain, University of Minnesota, 2025 E. River Parkway, Minneapolis, MN 55414, USA. ²Department of Cognitive Science, University of California San Diego, San Diego, USA. ³Department of Psychiatry and Behavioral Sciences, University of Minnesota, Minneapolis, USA. ⁴Masonic Institute for the Developing Brain, University of Minnesota Informatics Institute, Minneapolis, USA. ⁵Non-Invasive Neuromodulation Lab, Brain Conditions, MnDRIVE Initiative, University of Minnesota, Minneapolis, USA. ⁶Neuroscience Program, Research Department, Gillette Children's Specialty Healthcare, Saint Paul, USA. ⁷School of Public Health, Division of Biostatistics, University of Minnesota, Minneapolis, USA. ⁸Department of Biomedical Engineering, University of Minnesota, Minneapolis, USA.

Received: 17 May 2023 Accepted: 13 June 2023

Published online: 03 July 2023

References

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5®). Arlington, VA: American Psychiatric Pub; 2013.
2. Centers for Disease Control and Prevention (CDC). Prevalence of diagnosed Tourette syndrome in persons aged 6–17 years - United States, 2007. *MMWR Morb Mortal Wkly Rep.* 2009;58(21):581–5.
3. Conelea CA, Woods DW, Zinner SH, Budman C, Murphy T, Scahill LD, et al. Exploring the impact of chronic tic disorders on youth: results from the Tourette Syndrome Impact Survey. *Child Psychiatry Hum Dev.* 2011;42(2):219–42.
4. Fernández de la Cruz L, Rydell M, Runeson B, Brander G, Rück C, D'Onofrio BM, et al. Suicide in Tourette's and chronic tic disorders. *Biol Psychiatry.* 2017;82(2):111–8.
5. Zinner SH, Conelea CA, Glew GM, Woods DW, Budman CL. Peer victimization in youth with Tourette syndrome and other chronic tic disorders. *Child Psychiatry Hum Dev.* 2012;43(1):124–36.
6. Woods DW, Piacentini J, Chang S, Deckersbach T, Ginsburg G, Peterson A, et al. Managing Tourette syndrome: a behavioral intervention for children and adults therapist guide. New York, NY: Oxford University Press; 2008. p. 144.
7. Pringsheim T, Okun MS, Müller-Vahl K, Martino D, Jankovic J, Cavanna AE, et al. Practice guideline recommendations summary: treatment of tics in people with Tourette syndrome and chronic tic disorders. *Neurology.* 2019;92(19):896–906.
8. Piacentini J, Woods DW, Scahill L, Wilhelm S, Peterson AL, Chang S, et al. Behavior therapy for children with Tourette disorder: a randomized controlled trial. *JAMA.* 2010;303(19):1929–37.
9. Wilhelm S, Peterson AL, Piacentini J, Woods DW, Deckersbach T, Sukhodolsky DG, et al. Randomized trial of behavior therapy for adults with Tourette syndrome. *Arch Gen Psychiatry.* 2012;69(8):795–803.
10. McGuire JF, Piacentini J, Brennan EA, Lewin AB, Murphy TK, Small BJ, et al. A meta-analysis of behavior therapy for Tourette syndrome. *J Psychiatr Res.* 2014;50:106–12.
11. McGuire JF, Ricketts EJ, Piacentini J, Murphy TK, Storch EA, Lewin AB. behavior therapy for tic disorders: an evidenced-based review and new directions for treatment research. *Curr Dev Disord Rep.* 2015;2(4):309–17.
12. Kim S, Greene DJ, Robichaux-Viehoever A, Bihun EC, Koller JM, Acevedo H, et al. Tic suppression in children with recent-onset tics predicts 1-year tic outcome. *J Child Neurol.* 2019;34(12):757–764.
13. Himle MB, Woods DW. An experimental evaluation of tic suppression and the tic rebound effect. *Behav Res Ther.* 2005;43(11):1443–51.

14. Conelea CA, Wellen B, Woods DW, Greene DJ, Black KJ, Specht M, et al. Patterns and predictors of tic suppressibility in youth with tic disorders. *Front Psychiatry*. 2018;9:188.
15. Wang Z, Maia TV, Marsh R, Colibazzi T, Gerber A, Peterson BS. The neural circuits that generate tics in Tourette's syndrome. *Am J Psychiatry*. 2011;168(12):1326–37.
16. Mink JW. Neurobiology of basal ganglia and Tourette syndrome: basal ganglia circuits and thalamocortical outputs. *Adv Neurol*. 2006;99:89–98.
17. Nachev P, Kennard C, Husain M. Functional role of the supplementary and pre-supplementary motor areas. *Nat Rev Neurosci*. 2008;9(11):856–69.
18. Hampson M, Tokoglu F, King RA, Constable RT, Leckman JF. Brain areas coactivating with motor cortex during chronic motor tics and intentional movements. *Biol Psychiatry*. 2009;65(7):594–9.
19. Franzkowiak S, Pollok B, Biermann-Ruben K, Südmeyer M, Paszek J, Thomalla G, et al. Motor-cortical interaction in Gilles de la Tourette syndrome. *PLoS ONE*. 2012;7(1): e27850.
20. Bohlhalter S, Goldfine A, Matteson S, Garraux G, Hanakawa T, Kansaku K, et al. Neural correlates of tic generation in Tourette syndrome: an event-related functional MRI study. *Brain*. 2006;129(Pt 8):2029–37.
21. Stern E, Silbersweig DA, Chee KY, Holmes A, Robertson MM, Trimble M, et al. A functional neuroanatomy of tics in Tourette syndrome. *Arch Gen Psychiatry*. 2000;57(8):741–8.
22. Worbe Y, Malherbe C, Hartmann A, Péligrini-Issac M, Messé A, Vidailhet M, et al. Functional immaturity of cortico-basal ganglia networks in Gilles de la Tourette syndrome. *Brain*. 2012;135(Pt 6):1937–46.
23. Zappalò L, Porta M, Paulesu E. The anarchic brain in action: the contribution of task-based fMRI studies to the understanding of Gilles de la Tourette syndrome. *Curr Opin Neurol*. 2015;28(6):604–11.
24. Fox MD, Buckner RL, Liu H, Chakravarty MM, Lozano AM, Pascual-Leone A. Resting-state networks link invasive and noninvasive brain stimulation across diverse psychiatric and neurological diseases. *Proc Natl Acad Sci U S A*. 2014;111(41):E4367–75.
25. Conelea CA, McLaughlin NCR. Transcranial magnetic stimulation in Tourette syndrome and obsessive-compulsive disorder. In: *Neurotechnology and Brain Stimulation in Pediatric Psychiatric and Neurodevelopmental Disorders*. 2019. p. 189–215. <https://doi.org/10.1016/b978-0-12-812777-3.00008-8>
26. Thut G, Pascual-Leone A. A review of combined TMS-EEG studies to characterize lasting effects of repetitive TMS and assess their usefulness in cognitive and clinical neuroscience. *Brain Topogr*. 2010;22(4):219–32.
27. Mantovani A, Leckman JF, Grantz H, King RA, Sporn AL, Lisanby SH. Repetitive transcranial magnetic stimulation of the supplementary motor area in the treatment of Tourette syndrome: report of two cases. *Clin Neurophysiol*. 2007;118(10):2314–5.
28. Bloch Y, Arad S, Levkovitz Y. Deep TMS add-on treatment for intractable Tourette syndrome: a feasibility study. *World J Biol Psychiatry*. 2016;17(7):557–61.
29. Münchau A, Bloem BR, Thilo KV, Trimble MR, Rothwell JC, Robertson MM. Repetitive transcranial magnetic stimulation for Tourette syndrome. *Neurology*. 2002;59(11):1789–91.
30. Orth M, Kirby R, Richardson MP, Snijders AH, Rothwell JC, Trimble MR, et al. Subthreshold rTMS over pre-motor cortex has no effect on tics in patients with Gilles de la Tourette syndrome. *Clin Neurophysiol*. 2005;116(4):764–8.
31. Le K, Liu L, Sun M, Hu L, Xiao N. Transcranial magnetic stimulation at 1 hertz improves clinical symptoms in children with Tourette syndrome for at least 6 months. *J Clin Neurosci*. 2013;20(2):257–62.
32. Wu SW, Maloney T, Gilbert DL, Dixon SG, Horn PS, Huddleston DA, et al. Functional MRI-navigated repetitive transcranial magnetic stimulation over supplementary motor area in chronic tic disorders. *Brain Stimul*. 2014;7(2):212–8.
33. Kwon HJ, Lim WS, Lim MH, Lee SJ, Hyun JK, Chae JH, et al. 1-Hz low frequency repetitive transcranial magnetic stimulation in children with Tourette's syndrome. *Neurosci Lett*. 2011;492(1):1–4.
34. Mantovani A, Lisanby SH, Pieraccini F, Ulivelli M, Castrogiovanni P, Rossi S. Repetitive transcranial magnetic stimulation (rTMS) in the treatment of obsessive-compulsive disorder (OCD) and Tourette's syndrome (TS). *Int J Neuropsychopharmacol*. 2006;9(1):95–100.
35. Landeros-Weisenberger A, Mantovani A, Motlagh MG, de Alvarenga PG, Katsovich L, Leckman JF, et al. Randomized sham controlled double-blind trial of repetitive transcranial magnetic stimulation for adults with severe Tourette syndrome. *Brain Stimul*. 2015;8(3):574–81.
36. Silvanto J, Pascual-Leone A. State-dependency of transcranial magnetic stimulation. *Brain Topogr*. 2008;21(1):1–10.
37. Silvanto J, Muggleton N, Walsh V. State-dependency in brain stimulation studies of perception and cognition. *Trends Cogn Sci*. 2008;12(12):447–54.
38. Bikson M, Rahman A. Origins of specificity during tDCS: anatomical, activity-selective, and input-bias mechanisms. *Front Hum Neurosci*. 2013;7:688.
39. Leckman JF, Riddle MA, Hardin MT, Ort SI, Swartz KL, Stevenson J, et al. The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity. *J Am Acad Child Adolesc Psychiatry*. 1989;28(4):566–73.
40. Fried PJ, Santarnecchi E, Antal A, Bartres-Faz D, Bestmann S, Carpenter LL, et al. Training in the practice of noninvasive brain stimulation: recommendations from an IFCN committee. *Clin Neurophysiol*. 2021;132(3):819–37.
41. Zafar N, Paulus W, Sommer M. Comparative assessment of best conventional with best theta burst repetitive transcranial magnetic stimulation protocols on human motor cortex excitability. *Clin Neurophysiol*. 2008;119(6):1393–9.
42. Lazzaro VD, Di Lazzaro V, Dileone M, Pilato F, Capone F, Musumeci G, et al. Modulation of motor cortex neuronal networks by rTMS: comparison of local and remote effects of six different protocols of stimulation. *J Neurophysiol*. 2011;115:2150–6. <https://doi.org/10.1152/jn.00781.2010>
43. Allen CH, Kluger BM, Buard I. Safety of transcranial magnetic stimulation in children: a systematic review of the literature. *Pediatr Neurol*. 2017;68:3–17.
44. Hong YH, Wu SW, Pedapati EV, Horn PS, Huddleston DA, Laue CS, et al. Safety and tolerability of theta burst stimulation vs. single and paired pulse transcranial magnetic stimulation: a comparative study of 165 pediatric subjects. *Front Hum Neurosci*. 2015;9:29.
45. Install SimNIBS — SimNIBS 4.0.0 documentation. [cited 2023 Apr 12]. Available from: https://simnibs.github.io/simnibs/build/html/installation/simnibs_installer.html
46. Windhoff M, Opitz A, Thielscher A. Electric field calculations in brain stimulation based on finite elements: an optimized processing pipeline for the generation and usage of accurate individual head models. *Hum Brain Mapp*. 2013;34(4):923–35.
47. Opitz A, Paulus W, Will S, Antunes A, Thielscher A. Determinants of the electric field during transcranial direct current stimulation. *Neuroimage*. 2015;109:140–50.
48. Opitz A, Legon W, Rowlands A, Bickel WK, Paulus W, Tyler WJ. Physiological observations validate finite element models for estimating subject-specific electric field distributions induced by transcranial magnetic stimulation of the human motor cortex. *Neuroimage*. 2013;81:253–64.
49. Beynel L, Davis SW, Crowell CA, Hilbig SA, Lim W, Nguyen D, et al. Online repetitive transcranial magnetic stimulation during working memory in younger and older adults: a randomized within-subject comparison. *PLoS ONE*. 2019;14(3): e0213707.
50. Flancbaum M, Rockmore L, Franklin ME. Intensive behavior therapy for tics: implications for clinical practice and overcoming barriers to treatment. *J Dev Phys Disabil*. 2011;23(1):61–9.
51. Blount TH, Lockhart ALT, Garcia RV, Raj JJ, Peterson AL. Intensive outpatient comprehensive behavioral intervention for tics: a case series. *World J Clin Cases*. 2014;2(10):569–77.
52. Snow G, Snow MG. Package "blockrand." The Comprehensive R Archive Network. 2013; Available from: <https://cran.microsoft.com/snapshot/2014-12-06/web/packages/blockrand/blockrand.pdf>
53. Piacentini J, Himle MB, Chang S, Baruch DE, Buzzella BA, Pearlman A, et al. Reactivity of tic observation procedures to situation and setting. *J Abnorm Child Psychol*. 2006;34(5):649–58.
54. Himle MB, Chang S, Woods DW, Pearlman A, Buzzella B, Bunaciu L, et al. Establishing the feasibility of direct observation in the assessment of tics in children with chronic tic disorders. *J Appl Behav Anal*. 2006;39(4):429–40.
55. Team D. Datavyu: a video coding tool. Databrary Project, New York University. 2014. URL <http://datavyu.org>.
56. McHugh ML. Interrater reliability: the kappa statistic. *Biochem Med*. 2012;22(3):276–82.
57. Nielsen AN, Greene DJ, Gratton C, Dosenbach NUF, Petersen SE, Schlaggar BL. Evaluating the prediction of brain maturity from

- functional connectivity after motion artifact denoising. *Cereb Cortex*. 2019;29(6):2455–69.
58. Greene DJ, Koller JM, Hampton JM, Wesevich V, Van AN, Nguyen AL, et al. Behavioral interventions for reducing head motion during MRI scans in children. *Neuroimage*. 2018;171:234–45.
 59. Drobyshevsky A, Baumann SB, Schneider W. A rapid fMRI task battery for mapping of visual, motor, cognitive, and emotional function. *Neuroimage*. 2006;31(2):732–44.
 60. Feczko E, Conan G, Marek S, Tervo-Clemmens B, Cordova M, Doyle O, et al. Adolescent brain cognitive development (ABCD) community MRI collection and utilities. *bioRxiv*. 2021 [cited 2023 May 15]. p. 2021.07.09.451638. Available from: <https://www.biorxiv.org/content/10.1101/2021.07.09.451638v1>
 61. Power JD, Barnes KA, Snyder AZ, Schlaggar BL, Petersen SE. Spurious but systematic correlations in functional connectivity MRI networks arise from subject motion. *Neuroimage*. 2012;59(3):2142–54.
 62. Power JD, Barnes KA, Snyder AZ, Schlaggar BL, Petersen SE. Steps toward optimizing motion artifact removal in functional connectivity MRI; a reply to Carp. *Neuroimage*. 2013;76:439–41.
 63. Power JD, Mitra A, Laumann TO, Snyder AZ, Schlaggar BL, Petersen SE. Methods to detect, characterize, and remove motion artifact in resting state fMRI. *Neuroimage*. 2014;84:320–41.
 64. Ciric R, Wolf DH, Power JD, Roalf DR, Baum GL, Ruparel K, et al. Benchmarking of participant-level confound regression strategies for the control of motion artifact in studies of functional connectivity. *Neuroimage*. 2017;154:174–87.
 65. Satterthwaite TD, Ciric R, Roalf DR, Davatzikos C, Bassett DS, Wolf DH. Motion artifact in studies of functional connectivity: characteristics and mitigation strategies. *Hum Brain Mapp*. 2019;40(7):2033–51.
 66. Greve DN, Fischl B. Accurate and robust brain image alignment using boundary-based registration. *Neuroimage*. 2009;48(1):63–72.
 67. Bernstein GA, Cullen KR, Harris EC, Conelea CA, Zagoloff AD, Carstedt PA, et al. Sertraline effects on striatal resting-state functional connectivity in youth with obsessive-compulsive disorder: a pilot study. *J Am Acad Child Adolesc Psychiatry*. 2019;58(5):486–95.
 68. Kim J, Wozniak JR, Mueller BA, Shen X, Pan W. Comparison of statistical tests for group differences in brain functional networks. *Neuroimage*. 2014;101:681–94.
 69. Seitzman BA, Gratton C, Marek S, Raut RV, Dosenbach NUF, Schlaggar BL, et al. A set of functionally-defined brain regions with improved representation of the subcortex and cerebellum. *Neuroimage*. 2020;206: 116290.
 70. Friedman J, Hastie T, Tibshirani R. Sparse inverse covariance estimation with the graphical lasso. *Biostatistics*. 2008;9(3):432–41.
 71. Fiecas M, Ombao H, van Lunen D, Baumgartner R, Coimbra A, Feng D. Quantifying temporal correlations: a test–retest evaluation of functional connectivity in resting-state fMRI. *Neuroimage*. 2013;65:231–41.
 72. Brier MR, Thomas JB, Snyder AZ, Benzinger TL, Zhang D, Raichle ME, et al. Loss of intranetwork and internetwork resting state functional connections with Alzheimer’s disease progression. *J Neurosci*. 2012;32(26):8890–9.
 73. Schorning K, Bornkamp B, Bretz F, Dette H. Model selection versus model averaging in dose finding studies. *Stat Med*. 2016;35(22):4021–40.
 74. Simon YH, Peter PJK, John H, Dearden C. Interval estimation of the 90% effective dose: a comparison of bootstrap resampling methods with some large-sample approaches. *J Appl Stat*. 2000;27(1):63–73.
 75. Policy governing independent safety monitors and independent data and safety monitoring boards. National Institute of Mental Health (NIMH). [cited 2023 Apr 3]. Available from: <https://www.nimh.nih.gov/funding/clinical-research/policy-governing-independent-safety-monitors-and-independent-data-and-safety-monitoring-boards>
 76. Center for Devices, Radiological Health. Sponsor’s Responsibilities For Significant Risk Device Investigations (Nov. 1995) [Internet]. U.S. Food and Drug Administration. FDA; [cited 2023 Apr 3]. Available from: <https://www.fda.gov/medical-devices/investigational-device-exemption-ide/sponsors-responsibilities-significant-risk-device-investigations-nov-1995>
 77. Conelea CA, Jacob S, Redish AD, Ramsay IS. Considerations for pairing cognitive behavioral therapies and non-invasive brain stimulation: ignore at your own risk. *Front Psychiatry*. 2021;12: 660180.
 78. Hameed MQ, Dhamne SC, Gersner R, Kaye HL, Oberman LM, Pascual-Leone A, et al. Transcranial magnetic and direct current stimulation in children. *Curr Neurol Neurosci Rep*. 2017;17(2):11.
 79. Nahum M, Lee H, Merzenich MM. Principles of neuroplasticity-based rehabilitation. *Prog Brain Res*. 2013;207:141–71.
 80. Kleim JA, Jones TA. Principles of experience-dependent neural plasticity: implications for rehabilitation after brain damage. *J Speech Lang Hear Res*. 2008;51(1):S225–39.
 81. Racine RJ, Chapman CA, Trepel C, Teskey GC, Milgram NW. Post-activation potentiation in the neocortex. IV. Multiple sessions required for induction of long-term potentiation in the chronic preparation. *Brain Res*. 1995;702(1–2):87–93.
 82. RESCINDED: NOT-MH-19–033: RESCINDED - Notice of Data Sharing Policy for the National Institute of Mental Health. [cited 2023 Apr 3]. Available from: <https://grants.nih.gov/grants/guide/notice-files/NOT-MH-19-033.html>

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.